JPH01240169A - Concentrated liquid food - Google Patents
Concentrated liquid foodInfo
- Publication number
- JPH01240169A JPH01240169A JP63063399A JP6339988A JPH01240169A JP H01240169 A JPH01240169 A JP H01240169A JP 63063399 A JP63063399 A JP 63063399A JP 6339988 A JP6339988 A JP 6339988A JP H01240169 A JPH01240169 A JP H01240169A
- Authority
- JP
- Japan
- Prior art keywords
- potassium
- concentrated liquid
- minerals
- liquid food
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000021056 liquid food Nutrition 0.000 title abstract description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 33
- 239000011707 mineral Substances 0.000 claims abstract description 33
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011591 potassium Substances 0.000 claims abstract description 18
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000002738 chelating agent Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 7
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 235000020888 liquid diet Nutrition 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 abstract description 12
- 230000001954 sterilising effect Effects 0.000 abstract description 9
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 8
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 3
- 238000001556 precipitation Methods 0.000 abstract description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 abstract description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 abstract description 2
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 229910001577 potassium mineral Inorganic materials 0.000 abstract 1
- 235000019983 sodium metaphosphate Nutrition 0.000 abstract 1
- 229940048086 sodium pyrophosphate Drugs 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 27
- 239000000047 product Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- -1 glucose and fructose Chemical class 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 208000007645 potassium deficiency Diseases 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 229910007541 Zn O Inorganic materials 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は手術前および手術後の患者に対して栄養補給の
目的で使用される濃厚流動食に関するものである。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a concentrated liquid diet used for the purpose of nutritional supplementation to patients before and after surgery.
(従来の技術)
現在、病院等で使用されている濃厚流動食には粉末タイ
プのものと液状タイプのものとがあるが、取扱いの簡便
性から液状タイプのものが好まれるようになってきてい
る。(Prior art) Currently, there are two types of concentrated liquid foods used in hospitals, etc.: powder type and liquid type, but liquid type is becoming preferred due to its ease of handling. There is.
一般に、液状タイプの製品には、数ケ月間の室温保存に
耐え得る乳化安定性、短時間に細いチューブを通過でき
るチューブ流動性、及び良好な風味などが要求される。Generally, liquid-type products are required to have emulsion stability that can withstand storage at room temperature for several months, tube fluidity that allows the product to pass through a narrow tube in a short time, and good flavor.
しかし、ミネラルを多く含有し、上記の条件に合致した
液状タイプの製品は見当らない。However, no liquid type product has been found that contains a large amount of minerals and meets the above conditions.
(発明が解決しようとする課題)
一方、従来の濃厚流動食に含有されているミネラル、ビ
タミンは、基準エネルギー量が1600kcal〜24
00kca lとして、日本人の栄養所要量を勘案して
配合されている。(Problem to be solved by the invention) On the other hand, the minerals and vitamins contained in conventional concentrated liquid foods have a standard energy content of 1600 kcal to 24 kcal.
00kcal, it is formulated taking into consideration the nutritional requirements of Japanese people.
しかし、老人及び脳血管障害のような患者には、投与エ
ネルギー量を少なくして、通常1000〜1400に’
calの投与が行われている。従って、現在の製品をこ
れらの患者に使用した場合、ミネラル、ビタミンの投与
量が少なくなり、栄養所要量を充足することができなく
なっている。However, for elderly patients and patients with cerebrovascular disorders, the amount of energy administered should be lower, usually 1000 to 1400.
Cal is being administered. Therefore, when current products are used in these patients, the doses of minerals and vitamins are reduced, making it impossible to meet nutritional requirements.
ミネラル、ビタミンは生体維持のために、体内で種々の
役割を持ち、中でもカリウムは細胞内に存在する主要カ
チオンであり、細胞内外の浸透圧維持を果たす重要なミ
ネラルの一つである。Minerals and vitamins have various roles in the body to maintain living organisms, and among them, potassium is a major cation present in cells and is one of the important minerals that maintains osmotic pressure inside and outside cells.
胃内の胃酸分泌量が低下している患者やそれ以外の患者
でも、一般健康人よりもミネラル吸収能力が低下してお
り、従来の濃厚流動食を投与した□ 場合に、カリウ
ム欠乏症になることが指摘されている。Even in patients with decreased gastric acid secretion in the stomach and other patients, the ability to absorb minerals is lower than in general healthy people, and if a conventional concentrated liquid diet is administered□, potassium deficiency may occur. has been pointed out.
現在、製品には前述のように粉末タイプと液状タイプが
あるが、粉末状のものは患者に投与するのに温湯で溶解
する必要があり、従ってそれらの、手間がかからない液
状タイプのものが好まれている。液状タイプの場合、ミ
ネラルを多く配合するとタンパク質が変性して凝集及び
クリーミングを起こしたりする。すなわち、従来の技術
では十分なミネラル量を含有し、長期にわたって安定な
乳化状の濃厚流動食の製造は難しいという問題があった
。Currently, there are powder and liquid types of products as mentioned above, but the powder type needs to be dissolved in warm water before being administered to the patient, so these less labor-intensive liquid types are preferred. It is rare. In the case of a liquid type, if too many minerals are added, the protein will denature and cause aggregation and creaming. That is, with the conventional technology, there was a problem in that it was difficult to produce an emulsified concentrated liquid food that contained a sufficient amount of minerals and was stable over a long period of time.
(課題を解決するための手段)
本発明はこれらの問題点を解決するために、ミネラル、
ビタミンの濃度を、特にカリウムの濃度を高くし、かつ
キレート剤を併用することにより非常に良好な乳化状の
濃厚流動食が得られることがわかり、本発明に到達した
。(Means for Solving the Problems) In order to solve these problems, the present invention provides minerals,
It was found that a very good emulsified concentrated liquid food can be obtained by increasing the concentration of vitamins, especially potassium, and also using a chelating agent, leading to the present invention.
すなわち本発明は、タンパク質又はその分解物、糖質、
脂質、ビタミン、ミネラルを主成分とする濃厚流動食に
おいて、ミネラル中のカリウム含量が全組成中に対し0
.07〜0.30重量%、カリウム以外のミネラル含量
が0.25〜1.0重量%であり、さらに0.02〜0
.15重量%のキレート剤を含有することを特徴とする
。That is, the present invention provides proteins or decomposition products thereof, carbohydrates,
In a concentrated liquid diet whose main ingredients are fat, vitamins, and minerals, the potassium content in the minerals is 0 compared to the total composition.
.. 07 to 0.30% by weight, mineral content other than potassium is 0.25 to 1.0% by weight, and further 0.02 to 0.
.. It is characterized by containing 15% by weight of a chelating agent.
カリウムの添加量は、全組成中0.07〜0.30重量
%であり、0.07重量%以下ではその機能が発揮され
ず、0.30重量%以以上上は逆に人体側への生理的負
担が大きくなる。The amount of potassium added is 0.07 to 0.30% by weight in the total composition, and if it is less than 0.07% by weight, its function will not be exhibited, and if it is more than 0.30% by weight, it will adversely affect the human body. Physiological burden increases.
日本人のカリウムの栄養所要量は2000〜4000m
gを目標摂取量とし、成人のカリウムの必要量は、1日
当たり体重1kg当たり、0.4ミリ当量(15,6e
1g)とされている。The nutritional requirement for potassium for Japanese people is 2000-4000m
The potassium requirement for adults is 0.4 milliequivalents (15.6 eq. g) per kg of body weight per day.
1g).
本発明のカリウム添加量は患者の摂取するエネルギー量
を1000〜1400kcal/日のエネルギー量とし
た場合でも、必要量のカリウムを十分に摂取できるよう
にしたものである。The amount of potassium added according to the present invention is such that even when the amount of energy ingested by the patient is 1000 to 1400 kcal/day, the necessary amount of potassium can be sufficiently ingested.
本発明は、カリウム以外に栄養上必要なミネラルが配合
される。それらのミネラルは主に、ナトリウム、カルシ
ウム、マグネシウム、鉄であり、それらの合計量として
0.25〜1.0重量%の範囲で配合される。実際は、
上記のカリウムと同様に患者へ1000〜1400kc
al /日のエネルギー量とした場合に必要量のミネラ
ルを摂取できるようにしたものである。In the present invention, nutritionally necessary minerals are added in addition to potassium. These minerals are mainly sodium, calcium, magnesium, and iron, and their total amount is in the range of 0.25 to 1.0% by weight. Actually,
1000-1400 kc to the patient as well as potassium above
It is designed so that the required amount of minerals can be ingested based on the amount of energy per day.
本発明は、タンパク質の不溶性防止のためにキレート剤
が配合される。使用するキレート剤は縮合リン酸塩から
選ばれる少なくとも1種類であることが好ましい。具体
的には、本発明に用いる十レート剤は、各種のリン酸ナ
トリウム、クエン酸ナトリウムであり、好ましくは、イ
タリン酸ナトリウム、酸性ビロリン酸ナトリウム、ピロ
リン酸四ナトリウム、ビロリン酸ナトリウム、ポリリン
酸ナトリウム、ウルトラリン酸塩などの縮合リン酸塩が
挙げられる。これらの添加量は、全組成中0.02〜0
.15重量%であるが、0.02重量%以下ではその効
果が発揮されず、また、0.15重量%までの範囲でそ
の効果が十分発揮されることから、それ以上は必要とし
ない。In the present invention, a chelating agent is added to prevent protein insolubility. The chelating agent used is preferably at least one type selected from condensed phosphates. Specifically, the decalate agents used in the present invention are various sodium phosphates and sodium citrate, preferably sodium italate, sodium acid birophosphate, tetrasodium pyrophosphate, sodium birophosphate, and sodium polyphosphate. , condensed phosphates such as ultraphosphates. The amount of these added is 0.02 to 0 in the total composition.
.. The amount is 15% by weight, but the effect is not exhibited at 0.02% by weight or less, and the effect is sufficiently exhibited up to 0.15% by weight, so no more than 0.02% by weight is required.
本発明の濃厚流動食は、人体に必要な栄養を十分に供給
するために、ミネラル以外にタンパク質、又はその分解
物、糖質、脂質、ビタミンおよび水を主成分とする。The concentrated liquid food of the present invention mainly contains protein or its decomposition products, carbohydrates, lipids, vitamins, and water in addition to minerals, in order to sufficiently supply the nutrients necessary for the human body.
本発明に使用されるタンパク質としては、消化吸収に優
れ、かつ栄養価の高いものが用いられる。The protein used in the present invention is one that is easily digested and absorbed and has high nutritional value.
例えば、乳タンパク質、大豆タンパク質、魚肉タンパク
質、肉タンパク質、卵タンパク質、ゼラチン等、および
これらの酵素分解物が挙げられ、1種単独又は2種以上
を組み合わせて使用できる。Examples include milk protein, soybean protein, fish protein, meat protein, egg protein, gelatin, etc., and enzymatic decomposition products thereof, which can be used alone or in combination of two or more.
本発明に使用する糖質としては、デンプン、デキストリ
ンおよびその加水分解物が使用される。The carbohydrates used in the present invention include starch, dextrin, and hydrolysates thereof.
また、ブドウ糖、果糖などの単糖類、マルトース、乳糖
などの三糖類なども1種単独又は2種以上組み合わせて
使用できる。Furthermore, monosaccharides such as glucose and fructose, and trisaccharides such as maltose and lactose can be used singly or in combination of two or more.
本発明に使用する脂質としては、大豆油、コーン油、ナ
タネ油、ヤシ油、ラード、牛脂、魚油などの加工油脂が
ある。The lipids used in the present invention include processed fats and oils such as soybean oil, corn oil, rapeseed oil, coconut oil, lard, beef tallow, and fish oil.
本発明には栄養上必要な各種ビタミンが配合される。そ
の配合量は、患者の1000〜1400Kcal 7日
のエネルギー量とした場合に、栄養所要量の各種ビタミ
ンを十分に摂取できるように配合される。The present invention contains various nutritionally necessary vitamins. The blending amount is such that the patient can fully ingest the nutritionally required amount of various vitamins when the patient's energy amount is 1000 to 1400 Kcal per 7 days.
また、必要に応じて、フレーバー類や果汁などを添加し
ても良い。Further, flavors, fruit juice, etc. may be added as necessary.
本発明の濃厚流動食は、上記タンパク質およびその分解
物、糖質、脂質、ビタミンおよびミネラルを所定熱量、
すなわちI Kcal / mllになるように水で溶
解し、均質機を用いて均質化処理を行い、均一な乳化液
とした後、100〜150℃の高温滅菌処理を行って製
造される。滅菌手段としてはレトルト滅菌、超高温瞬間
滅菌などが採用される。レトルト滅菌は、均質液をビン
、缶、レトルトパウチなどの包装容器に充填密封したも
のを、オートクレーブで加熱滅菌するもので、100〜
135℃、3秒〜30分の条件で滅菌が行われる。The concentrated liquid food of the present invention contains the above proteins and their decomposition products, carbohydrates, lipids, vitamins and minerals in a predetermined amount of heat and
That is, it is manufactured by dissolving it in water to a concentration of I Kcal/ml, performing homogenization using a homogenizer to obtain a uniform emulsion, and then performing high temperature sterilization at 100 to 150°C. Retort sterilization, ultra-high temperature instant sterilization, etc. are used as sterilization methods. Retort sterilization involves filling and sealing a homogeneous liquid into packaging containers such as bottles, cans, and retort pouches, and heating and sterilizing them in an autoclave.
Sterilization is performed at 135° C. for 3 seconds to 30 minutes.
(作用)
こうして得られる濃厚流動食は、粘度が5〜20cp(
10℃)であり、経口および経管により、胃、腸等の消
化器官に簡便かつ安定して供給できる。(Function) The concentrated liquid food thus obtained has a viscosity of 5 to 20 cp (
10°C), and can be easily and stably supplied to digestive organs such as the stomach and intestines by oral route or tube.
本発明の濃厚流動食は、−日の投与エネルギー量の少な
い、またはミネラルの吸収能力が低下しいる脳血管障害
者および老人のような患者に対して、ミネラル、ビタミ
ンの栄養所要量を投与することができ、それらの欠乏症
を防止することができる。The concentrated liquid diet of the present invention administers the required nutritional amount of minerals and vitamins to patients with cerebrovascular disease and the elderly who have a low amount of energy to administer on a day or have a decreased ability to absorb minerals. and their deficiencies can be prevented.
(発明の効果)
本発明は、ミネラルの含有量の高い濃厚流動食であり、
キレート剤を用いることで以下のような効果が得られる
。(Effect of the invention) The present invention is a concentrated liquid food with high mineral content,
The following effects can be obtained by using a chelating agent.
(11−年間室温に保存しても、分離、沈澱、凝集を起
こさない。(No separation, precipitation, or aggregation occurs even when stored at room temperature for 11 years.
(2)滅菌処理後においても、良好な乳化安定性を保ち
、チューブ流動性に優れ、下痢等の副作用もない。(2) Even after sterilization, it maintains good emulsion stability, has excellent tube fluidity, and has no side effects such as diarrhea.
(3)液状製品であるので、直ちに経口又は経管によっ
て投与でき、栄養的にも優れている。(3) Since it is a liquid product, it can be administered immediately orally or via tube, and is nutritionally superior.
(実施例)
つぎに本発明を実施例、比較例および試験例により詳細
に説明する。以下、%は重量基準である。(Examples) Next, the present invention will be explained in detail using Examples, Comparative Examples, and Test Examples. Hereinafter, percentages are based on weight.
実施例1
39.6kgの水に、52.3gのへキサメタリン酸ナ
トリウム(0,1%に相当)を溶解させ、この液に2.
11kgのカゼインナトリウム、1.16kgのホエー
タンパク質、9.7kgのデキストリンを添加し溶解さ
せた。Example 1 52.3 g of sodium hexametaphosphate (equivalent to 0.1%) was dissolved in 39.6 kg of water, and 2.
11 kg of sodium caseinate, 1.16 kg of whey protein, and 9.7 kg of dextrin were added and dissolved.
一方、400gの大豆油、50gのサフラワー油、およ
び42.5gのレシチンを配合し、30gのデカグリセ
リンモノラウレートを添加し、溶解した。この配合した
脂質を、上記水溶液に混合し、さらに第1表に示す配合
割合で配合した8、2gのビタミンミックスと434.
3gのミネラルミックスとを混合して、プロペラ式攪拌
機で70℃、15分間、予備乳化させた。Meanwhile, 400 g of soybean oil, 50 g of safflower oil, and 42.5 g of lecithin were blended, and 30 g of decaglycerin monolaurate was added and dissolved. This blended lipid was mixed with the above aqueous solution, and further mixed with 8.2 g of vitamin mix at the blending ratio shown in Table 1.
The mixture was mixed with 3 g of mineral mix and pre-emulsified at 70° C. for 15 minutes using a propeller stirrer.
この予備乳化液を、1段目200kg / cnl、2
段目50kg/calの2段均質化で均質処理を1行い
、乳化液を得た。This preliminary emulsion was added to the first stage, 200 kg/cnl, 2
One homogenization process was performed by two-stage homogenization at 50 kg/cal to obtain an emulsion.
この乳化液を、400 mlずつ缶に充填密封し、直ち
にオートクレーブ内で、115℃、15分間レトルト滅
菌し、缶入りの濃厚流動食を得た。400 ml of this emulsion was filled into cans and sealed, and immediately retort sterilized in an autoclave at 115°C for 15 minutes to obtain canned concentrated liquid food.
この製品の栄養組成を第2表に示す。The nutritional composition of this product is shown in Table 2.
この液のエネルギーは、1.0Kcal/WIlである
。この濃厚流動食を1年間放置したところ、離水、油分
分離は認められず、乳化安定性は良好であった。The energy of this liquid is 1.0 Kcal/WIl. When this concentrated liquid food was left for one year, no syneresis or oil separation was observed, and the emulsion stability was good.
実施例2
実施例1においてへキサメタリン酸ナトリウムの代わり
に、78.3 gのクエン酸ナトリウムおよび、第3表
に示したミネラル組成で711.5gのミネラルミック
スを混合し、この乳化液を、スタンディングパウチに充
填した以外は全て実施例1に準じて、濃厚流動食を得た
。Example 2 Instead of sodium hexametaphosphate in Example 1, 78.3 g of sodium citrate and 711.5 g of a mineral mix having the mineral composition shown in Table 3 were mixed, and this emulsion was poured into a standing liquid. A concentrated liquid food was obtained in the same manner as in Example 1 except that it was filled into a pouch.
この濃厚流動食を1年間放置したところ、離水、油分分
離は認められず、乳化安定性は良好であった。When this concentrated liquid food was left for one year, no syneresis or oil separation was observed, and the emulsion stability was good.
第4表に、この製品のミネラルの含量を示した。Table 4 shows the mineral content of this product.
実施例3〜5、比較例1.2
第5表に示すカリウム塩とキレート剤を用いて実施例2
と同様に濃厚流動食を得た。Examples 3 to 5, Comparative Example 1.2 Example 2 using the potassium salt and chelating agent shown in Table 5
A concentrated liquid diet was obtained in the same manner.
茅上表 (全組成100g当り)
一ビタミン類−
ビタミンA 粉末 1 、49mgビタ
ミンB1塩酸チアミン 0.06mgビタミンB
2リン酸リボフラビン 0.06mgビタミンB6塩酸
ピリドキシン 0.23mgビタミンC2・85mg
ビタミンD 粉末(200000111/g) 0.
03mgビタミンE 粉末(20χ) 8.
55mgニコチン酸アミド 1.43
mgパントテン酸カルシウム 0.57mg葉
酸 0.23mg−ミネラ
ル類−
塩化ナトリウム 0.14g塩化カリ
ウム 0.32g炭酸カリウム
0.04gグリセロリン酸カルシウム
0.17g硫酸第一鉄 1
.14−g塩化マグネシウム 0.10
g玉1表 (全組成100g当り)
タンパク質 5.09g脂質
0.92g糖質
15.97g−ビタミン類−
ビタミンA 102.78 II
ビタミンB+ 0.06mgビ
タミンB z 0.06mgビ
タミンB 6 0.25mgビタ
ミンB l! 0.34mgビタ
ミンC2,85mg
ビタミビタミン 17.0910ビタ
ミンE 2.06mgビタミン
に+ 9.11ggニコチン酸
アミド 1 、46mgパントテン酸
0.64mg葉酸
24.38x−ミネラル類−
Na 106.65m
gK 188.23m
gCa 39.1
9n+gFe O
,69+ag”g
13.44BP
3B 、 29mgMn
0.01mgCu
6.83河Zn
O,19mgCl
142.20鋼g第1犬 (全組成100g
当り)
塩化ナトリウム 0.12g塩化カリ
ウム 0.49gグリセロリン酸カ
ルシウム 0 、55g硫酸第一鉄
1.54mg塩化マグネシウム
0.10g策土表 (全組成100g当り)
一ミネラル類−
Na 92.59m
gK 259.26m
gCa 129.63
mgFe O,93
5g”8 1
3.98mgP
96.29mgM’
0.01mgCu
6.83mgZn
0.19m
gCl 1
85.29mg五W狡
実施例1〜5、比較例1.2を用いて、乳化安定性、平
均粒径について、性能試験を行い、その結果を第5表に
示す。第5表の結果から、本発明の製品は製造直後およ
び1年間保存後でも乳化安定性が著しく優れていること
が明らかであり、経口および経管による。栄養補給に使
用することができた。Kaya table (per 100g of total composition) Vitamins - Vitamin A powder 1, 49mg Vitamin B1 Thiamine hydrochloride 0.06mg Vitamin B
Riboflavin diphosphate 0.06mg Vitamin B6 Pyridoxine hydrochloride 0.23mg Vitamin C2 85mg Vitamin D powder (200000111/g) 0.
03mg vitamin E powder (20χ) 8.
55mg Nicotinic acid amide 1.43
mg Calcium pantothenate 0.57 mg Folic acid 0.23 mg - Minerals - Sodium chloride 0.14 g Potassium chloride 0.32 g Potassium carbonate
0.04g calcium glycerophosphate 0.17g ferrous sulfate 1
.. 14-g magnesium chloride 0.10
1 g ball (per 100g of total composition) Protein 5.09g Lipid
0.92g carbohydrates
15.97g - Vitamins - Vitamin A 102.78 II
Vitamin B+ 0.06mg Vitamin B z 0.06mg Vitamin B 6 0.25mg Vitamin B l! 0.34mg Vitamin C2, 85mg Vitamin Vitamin 17.0910 Vitamin E 2.06mg Vitamin + 9.11gg Nicotinamide 1, 46mg Pantothenic Acid
0.64mg folic acid
24.38x-Minerals-Na 106.65m
gK 188.23m
gCa 39.1
9n+gFeO
,69+ag”g
13.44BP
3B, 29mgMn
0.01mg Cu
6.83 River Zn
O, 19mgCl
142.20g steel 1st dog (total composition 100g
per) Sodium chloride 0.12g Potassium chloride 0.49g Calcium glycerophosphate 0, 55g Ferrous sulfate
1.54mg magnesium chloride
0.10g soil surface (per 100g of total composition) Minerals - Na 92.59m
gK 259.26m
gCa 129.63
mgFeO,93
5g”8 1
3.98mgP
96.29mgM'
0.01mg Cu
6.83mgZn
0.19m
gCl 1
Performance tests were conducted on emulsion stability and average particle size using 85.29mg 5W Examples 1 to 5 and Comparative Example 1.2, and the results are shown in Table 5. From the results in Table 5, it is clear that the products of the present invention have extremely excellent emulsion stability immediately after manufacture and after storage for one year, and are administered orally and by tube. It could be used for nutritional supplementation.
偶力」&狡
実施例1〜5で得た濃厚流動食を(1kcal/ml)
を用いて、入院患者5名について投与試験を行い市販品
A(カリウム含量0.05重量%、その他のミネラル含
10.36重量%)のものと比較した。The concentrated liquid food obtained in Examples 1 to 5 (1 kcal/ml)
An administration test was conducted on 5 hospitalized patients using this product, and comparison was made with commercially available product A (potassium content: 0.05% by weight, other mineral content: 10.36% by weight).
第6表に14〜57日間の投与における臨床経過を示し
た。Table 6 shows the clinical course during administration for 14 to 57 days.
第6表の結果から、市販品Aは血清カリウム量が有意に
減少しており、カリウム欠乏症状を示したが、実施例1
〜5の本発明の製品は血清カリウム量の減少は認められ
ず、良好な栄養状態を示した。さらに、本発明を用いた
患者については、下痢及び腹部膨張窓は全く認められず
、臨床試験項目についても良好な結果が得られた。From the results in Table 6, commercial product A had a significant decrease in serum potassium level and exhibited potassium deficiency symptoms, but Example 1
In the products of the present invention No. 5 to 5, no decrease in serum potassium was observed, indicating good nutritional status. Furthermore, in patients treated with the present invention, no diarrhea or abdominal distention windows were observed, and good results were obtained in terms of clinical test items.
すなわち、本発明の製品は、副作用がなく、良好な栄養
補給を行い得ることが認められた。That is, it was confirmed that the product of the present invention has no side effects and can provide good nutritional support.
Claims (1)
ミン、ミネラルを主成分とする濃厚流動食において、ミ
ネラル中のカリウム含量が全組成中に対し0.07〜0
.30重量%、カリウム以外のミネラル含量が0.25
〜1.0重量%であり、さらに0.02〜0.15重量
%のキレート剤を含有することを特徴とする濃厚流動食
。(1) In a concentrated liquid diet whose main components are protein or its decomposition products, carbohydrates, lipids, vitamins, and minerals, the potassium content in the minerals is 0.07 to 0 in the total composition.
.. 30% by weight, mineral content other than potassium is 0.25
-1.0% by weight, and further contains 0.02-0.15% by weight of a chelating agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63063399A JP2700122B2 (en) | 1988-03-18 | 1988-03-18 | Rich liquid food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63063399A JP2700122B2 (en) | 1988-03-18 | 1988-03-18 | Rich liquid food |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01240169A true JPH01240169A (en) | 1989-09-25 |
JP2700122B2 JP2700122B2 (en) | 1998-01-19 |
Family
ID=13228188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63063399A Expired - Fee Related JP2700122B2 (en) | 1988-03-18 | 1988-03-18 | Rich liquid food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2700122B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003948A1 (en) * | 1989-09-14 | 1991-04-04 | Otsuka Pharmaceutical Co., Ltd. | Liquid nutrient composition |
WO1991015127A1 (en) * | 1990-04-06 | 1991-10-17 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
JP2008301723A (en) * | 2007-06-05 | 2008-12-18 | Nof Corp | Emulsified multiple nutritious food |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56123922A (en) * | 1980-02-01 | 1981-09-29 | Agronomique Inst Nat Rech | Treatment of substance based on casein* product obtained thereby and medicinal composition containing same |
JPS602153A (en) * | 1983-06-20 | 1985-01-08 | Fuji Oil Co Ltd | Alkaline earth metal enriching agent and preparation of protein composition enriched with alkaline earth metal |
JPS61500468A (en) * | 1983-11-24 | 1986-03-20 | フア−マコンソルト オサケヒユ− | Composition for food additives |
JPS6232856A (en) * | 1985-08-06 | 1987-02-12 | Ajinomoto Co Inc | Food or seasoning containing potassium |
JPS6232855A (en) * | 1985-08-06 | 1987-02-12 | Ajinomoto Co Inc | Food or seasoning containing potassium |
-
1988
- 1988-03-18 JP JP63063399A patent/JP2700122B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56123922A (en) * | 1980-02-01 | 1981-09-29 | Agronomique Inst Nat Rech | Treatment of substance based on casein* product obtained thereby and medicinal composition containing same |
JPS602153A (en) * | 1983-06-20 | 1985-01-08 | Fuji Oil Co Ltd | Alkaline earth metal enriching agent and preparation of protein composition enriched with alkaline earth metal |
JPS61500468A (en) * | 1983-11-24 | 1986-03-20 | フア−マコンソルト オサケヒユ− | Composition for food additives |
JPS6232856A (en) * | 1985-08-06 | 1987-02-12 | Ajinomoto Co Inc | Food or seasoning containing potassium |
JPS6232855A (en) * | 1985-08-06 | 1987-02-12 | Ajinomoto Co Inc | Food or seasoning containing potassium |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003948A1 (en) * | 1989-09-14 | 1991-04-04 | Otsuka Pharmaceutical Co., Ltd. | Liquid nutrient composition |
GB2245140A (en) * | 1989-09-14 | 1992-01-02 | Otsuka Pharma Co Ltd | Liquid nutrient composition |
GB2245140B (en) * | 1989-09-14 | 1993-07-07 | Otsuka Pharma Co Ltd | Nutrient fluid composition |
WO1991015127A1 (en) * | 1990-04-06 | 1991-10-17 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
JP2008301723A (en) * | 2007-06-05 | 2008-12-18 | Nof Corp | Emulsified multiple nutritious food |
Also Published As
Publication number | Publication date |
---|---|
JP2700122B2 (en) | 1998-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0129418B1 (en) | Infant foods | |
US4670285A (en) | Infant formula | |
US6288116B1 (en) | Method of administration of a nutritional product to a person having renal failure | |
JP2010527590A (en) | Acidic liquid breastfeeding supplements | |
EP0587824A1 (en) | Nutritional product for persons receiving renal dialysis. | |
WO2006112998A1 (en) | Liquid nutritional product to supplement human milk | |
EP2592938B1 (en) | Dairy product and process | |
JPS6236645B2 (en) | ||
JP5404558B2 (en) | Nutritional composition that can adjust the amount of energy, the amount of water and the amount converted to salt | |
JPWO2008136420A1 (en) | Liquid nutritional composition containing whey protein at high concentration and method for producing the same | |
KR20100016068A (en) | Liquid nutritional composition containing sodium at high concentration and method of producing the same | |
US20040052918A1 (en) | High energy complete food or nutritional supplement, method for preparing same and uses thereof | |
TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
CN101406218B (en) | Liquid dairy food containing fish oil and method for producing the same | |
JPH01240169A (en) | Concentrated liquid food | |
JP2001316278A (en) | Liquid enteral nutrition composition | |
JP2002142720A (en) | Nutritional composition | |
JPH06135838A (en) | Oral and tubal nutrient composition | |
JPS63309162A (en) | Orally feeding and tube-feeding nutritive food and production thereof | |
JP3589807B2 (en) | Nutritional composition of liquid preparation adapted to each symptom of kidney disease patients | |
JPS6342510B2 (en) | ||
LT4266B (en) | Milk product enriched with ground eggshell | |
Gormican et al. | Nasogastric tube feedings: practical considerations in prescription and evaluation | |
JP3179555B2 (en) | Liquid prepared nutritional food for kidney disease patients | |
JPS63296663A (en) | Food for medical cure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |